In fact, GLP-1 activation that causes mild nausea is the same mechanism driving the medication's weight-loss effectiveness
North Carolina eliminated GLP-1 coverage beginning October 2025 due to a budget stalemate in the legislature, but coverage was reinstated in December 2025, bringing the total number of states covering GLP-1s for obesity to 13 as of January 2026
Medical Writing/Editorial Assistance The authors acknowledge Lynn Buckley PhD, Medical Writer, Eli Lilly and Company, for providing project management support, and employees of Eli Lilly and Company for providing medical and statistical review support in the preparation of this manuscript
rival Eli Lilly, maker of Zepbound, Mounjaro and Foundayo, has been booming, even as employers and health plans push back against covering their cost
At these temperatures, the semaglutide molecules remain stable and the medication retains its full potency until the printed expiry date on the packaging